XXXX therapy for @entity548 .

@entity1 @entity548 @entity1161 @entity4272 @entity33 @entity406 @entity3504 @entity3503
BACKGROUND: Radiotherapy within pelvis is a vital component of curative therapy for urological, gynecological and rectal malignances. Rectum is especially vulnerable to @entity1161 resulting in @entity4272 . The most common and life-threatening symptom is @entity548 . @entity406 application into the rectum causes local cauterization of @entity33 . The aim of our study was to assess the efficacy of local @entity406 application in @entity1 with @entity548 . METHODS: A solution of 4.0% @entity406 was used in the treatment of 20 @entity1 with clinical and proctoscopic evidence of radiadion @entity4272 . Treatment involved direct application of 4.0% @entity406 into the rectum. All @entity1 were followed-up in terms of complete resolution of symptoms or recurrences of @entity548 . RESULTS: A total of 20 @entity1 with a mean age of 69.7 (range, 57-80) years were followed for 51.2 (range, 1-93) months. The mean duration of symptoms was 4.5 (range, 1-10) months and the interval between the end of radiotherapy and symptoms was mostly between 5 and 30 months. @entity1 required an average of 2 (range, 1-5) @entity406 treatments. Of the 20 @entity1 , 10 had complete resolution of their symptoms after their first treatment. In 10 @entity1 @entity548 recurred and they were offered another @entity406 instillation and/or @entity3504 suppositories and @entity3503 therapy. Complete resolution of symptoms was achieved in all @entity1 . CONCLUSIONS: Topical @entity406 instillation is effective, safe, and well-tolerated method for the @entity1 with @entity1161 . This therapy may be repeated in case of recurrent @entity548 and combined with other methods of treatment.
